Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase NA 2Phase 2/3 1Phase 1/2 1

Status

Completed 4Terminated 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 46Colorectal Neoplasms 42Neoplasms 41Neoplasm Metastasis 34Melanoma 31Multiple Myeloma 30Prostatic Neoplasms 29Recurrence 28Stomach Neoplasms 27Pancreatic Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lung Neoplasms 25Carcinoma, Renal Cell 25Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Leukemia, Myeloid, Acute 22Triple Negative Breast Neoplasms 21Lymphoma, Non-Hodgkin 21Lymphoma, Follicular 21Leukemia, Lymphocytic, Chronic, B-Cell 19Glioblastoma 19Uterine Cervical Neoplasms 16Myelodysplastic Syndromes 16Lymphoma 16Colonic Neoplasms 15Carcinoma, Transitional Cell 15Lymphoma, Mantle-Cell 14Leukemia 14

Interventions

onvansertib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Inflammatory Breast Neoplasms × Clear all
NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡